Maegim한국어

휴온스글로벌

084110KOSDAQSector: Pharma & Biotech
₩24,100▼ 1.03%Market cap ₩305.1BAs of Jul 21, 2026 close · updated once daily
A
Grade A68.6 ptsTop 14% of 2,523 stocks
Financial strength
66.8
Growth momentum
49.2
Price attractiveness
84.4

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

66.8
How much debt does it carry relative to equity?
Debt-to-equity ratio
43.0%
✓ Above median · Top 38.8% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
191.7%
✓ Above median · Top 49.8% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
10.7%
✓ Above median · Top 17.1% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
5.3%
✓ Above median · Top 27% in sector
Sector median -4.5%

Source filing: annual report (consolidated) — view original ↗

2

Growth momentum

49.2
How much did revenue grow in a year?
Revenue growth (YoY)
4.2%
✗ Below median · Top 58.2% in sector
Sector median 6.4%
Has it grown steadily over three years?
Revenue 3-year CAGR
8.5%
✓ Above median · Top 36.5% in sector
Sector median 4.9%
Did core profits grow in a year?
Operating income change (YoY)
-6.6%
✗ Below median · Top 59.2% in sector
Sector median 3.6%
Are core profits higher than three years ago?
Operating income change (3Y)
4.7%
✓ Above median · Top 49.2% in sector
Sector median 3.5%

Source filing: annual report (consolidated) — view original ↗

3

Price attractiveness

84.4
Is the price expensive relative to earnings?
P/E (price-to-earnings)
10.6x
✓ Above median · Top 15.2% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
0.56x
✓ Above median · Top 16.1% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15